|
1
|
MacLeod SL, Nowell S, Massengill J, Jazieh
A, McClure G, Plaxco J, Kadlubar FF and Lan NP: Cancer therapy and
polymorphisms of cytochromes P450. Clin Chem Lab Med. 38:883–887.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pavek P and Dvorak Z: Xenobiotic-induced
transcriptional regulation of xenobiotic metabolizing enzymes of
the cytochrome P450 superfamily in human extrahepatic tissues. Curr
Drug Metab. 9:129–143. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ding X and Kaminsky LS: Human extrahepatic
cytochromes P450: Function in xenobiotic metabolism and
tissue-selective chemical toxicity in the respiratory and
gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 43:149–173.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Krishna DR and Klotz U: Extrahepatic
metabolism of drugs in humans. Clin Pharmacokinet. 26:144–160.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rochat B: Role of cytochrome P450 activity
in the fate of anticancer agents and in drug resistance: Focus on
tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet.
44:349–366. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Michael M and Doherty MM: Tumoral drug
metabolism: Overview and its implications for cancer therapy. J
Clin Oncol. 23:205–229. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu LJ, Matias J, Scudiero DA, Hite KM,
Monks A, Sausville EA and Waxman DJ: P450 enzyme expression
patterns in the NCI human tumor cell line panel. Drug Metab Dispos.
29:304–312. 2001.PubMed/NCBI
|
|
8
|
Noll EM, Eisen C, Stenzinger A, Espinet E,
Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, et al:
CYP3A5 mediates basal and acquired therapy resistance in different
subtypes of pancreatic ductal adenocarcinoma. Nat Med. 22:278–287.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahmed S, Johnson K, Ahmed O and Iqbal N:
Advances in the management of colorectal cancer: From biology to
treatment. Int J Colorectal Dis. 29:1031–1042. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ciombor KK, Wu C and Goldberg RM: Recent
therapeutic advances in the treatment of colorectal cancer. Annu
Rev Med. 66:83–95. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gustavsson B, Carlsson G, Machover D,
Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of
the evolution of systemic chemotherapy in the management of
colorectal cancer. Clin Colorectal Cancer. 14:1–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Glimelius B: Benefit-risk assessment of
irinotecan in advanced colorectal cancer. Drug Saf. 28:417–433.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schmoll HJ, Van Cutsem E, Stein A,
Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde
CJ, Balmana J, Regula J, et al: ESMO consensus guidelines for
management of patients with colon and rectal cancer. A personalized
approach to clinical decision making. Ann Oncol. 23:2479–2516.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paulik A, Grim J and Filip S: Predictors
of irinotecan toxicity and efficacy in treatment of metastatic
colorectal cancer. Acta Medica (Hradec Kralove). 55:153–159. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lamba JK, Lin YS, Schuetz EG and Thummel
KE: Genetic contribution to variable human CYP3A-mediated
metabolism. Adv Drug Deliv Rev. 54:1271–1294. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lown KS, Bailey DG, Fontana RJ, Janardan
SK, Adair CH, Fortlage LA, Brown MB, Guo W and Watkins PB:
Grapefruit juice increases felodipine oral availability in humans
by decreasing intestinal CYP3A protein expression. J Clin Invest.
99:2545–2553. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bergheim I, Bode C and Parlesak A:
Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human
colon mucosa. BMC Clin Pharmacol. 5:42005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bergheim I, Bode C and Parlesak A:
Decreased expression of cytochrome P450 protein in non-malignant
colonic tissue of patients with colonic adenoma. BMC Gastroenterol.
5:342005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kumarakulasingham M, Rooney PH, Dundas SR,
Telfer C, Melvin WT, Curran S and Murray GI: Cytochrome p450
profile of colorectal cancer: Identification of markers of
prognosis. Clin Cancer Res. 11:3758–3765. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong N, Meng F, Wu Y, Wang M, Cui Y and
Zhang S: Genetic polymorphisms in cytochrome P450 and clinical
outcomes of FOLFIRI chemotherapy in patients with metastatic
colorectal cancer. Tumour Biol. 36:7691–7698. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koschny R, Krupp W, Xu LX, Mueller WC,
Bauer M, Sinn P, Keller M, Koschny T, Walczak H, Bruckner T, et al:
WHO grade related expression of TRAIL-receptors and apoptosis
regulators in meningioma. Pathol Res Pract. 211:109–116. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kolars JC, Lown KS, Schmiedlin-Ren P,
Ghosh M, Fang C, Wrighton SA, Merion RM and Watkins PB: CYP3A gene
expression in human gut epithelium. Pharmacogenetics. 4:247–259.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Anttila S, Hukkanen J, Hakkola J,
Stjernvall T, Beaune P, Edwards RJ, Boobis AR, Pelkonen O and
Raunio H: Expression and localization of CYP3A4 and CYP3A5 in human
lung. Am J Respir Cell Mol Biol. 16:242–249. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Raunio H, Hakkola J, Hukkanen J, Lassila
A, Päivärinta K, Pelkonen O, Anttila S, Piipari R, Boobis A and
Edwards RJ: Expression of xenobiotic-metabolizing CYPs in human
pulmonary tissue. Exp Toxicol Pathol. 51:412–417. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thörn M, Finnström N, Lundgren S, Rane A
and Lööf L: Cytochromes P450 and MDR1 mRNA expression along the
human gastrointestinal tract. Br J Clin Pharmacol. 60:54–60. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Westlind-Johnsson A, Malmebo S, Johansson
A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR and
Ingelman-Sundberg M: Comparative analysis of CYP3A expression in
human liver suggests only a minor role for CYP3A5 in drug
metabolism. Drug Metab Dispos. 31:755–761. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Koch I, Weil R, Wolbold R, Brockmöller J,
Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U
and Wojnowski L: Interindividual variability and tissue-specificity
in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos.
30:1108–1114. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bièche I, Narjoz C, Asselah T, Vacher S,
Marcellin P, Lidereau R, Beaune P and de Waziers I: Reverse
transcriptase-PCR quantification of mRNA levels from cytochrome
(CYP)1, CYP2 and CYP3 families in 22 different human tissues.
Pharmacogenet Genomics. 17:731–742. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Haehner BD, Gorski JC, Vandenbranden M,
Wrighton SA, Janardan SK, Watkins PB and Hall SD: Bimodal
distribution of renal cytochrome P450 3A activity in humans. Mol
Pharmacol. 50:52–59. 1996.PubMed/NCBI
|
|
32
|
Givens RC, Lin YS, Dowling AL, Thummel KE,
Lamba JK, Schuetz EG, Stewart PW and Watkins PB: CYP3A5 genotype
predicts renal CYP3A activity and blood pressure in healthy adults.
J Appl Physiol (1985). 95:1297–1300. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baron JM, Höller D, Schiffer R,
Frankenberg S, Neis M, Merk HF and Jugert FK: Expression of
multiple cytochrome p450 enzymes and multidrug
resistance-associated transport proteins in human skin
keratinocytes. J Invest Dermatol. 116:541–548. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lechevrel M, Casson AG, Wolf CR, Hardie
LJ, Flinterman MB, Montesano R and Wild CP: Characterization of
cytochrome P450 expression in human oesophageal mucosa.
Carcinogenesis. 20:243–248. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gervot L, Carrière V, Costet P, Cugnenc
PH, Berger A, Beaune PH and de Waziers I: CYP3A5 is the major
cytochrome P450 3A expressed in human colon and colonic cell lines.
Environ Toxicol Pharmacol. 2:381–388. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McKinnon RA, Burgess WM, Gonzalez FJ and
McManus ME: Metabolic differences in colon mucosal cells. Mutat
Res. 290:27–33. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Windmill KF, McKinnon RA, Zhu X, Gaedigk
A, Grant DM and McManus ME: The role of xenobiotic metabolizing
enzymes in arylamine toxicity and carcinogenesis: Functional and
localization studies. Mutat Res. 376:153–160. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sheweita SA: Drug-metabolizing enzymes:
Mechanisms and functions. Curr Drug Metab. 1:107–132. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Erichsen R, Baron JA, Hamilton-Dutoit SJ,
Snover DC, Torlakovic EE, Pedersen L, Frøslev T, Vyberg M, Hamilton
SR and Sørensen HT: Increased risk of colorectal cancer development
among patients with serrated polyps. Gastroenterology.
150:895–902.e5. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nusko G, Mansmann U, Partzsch U,
Altendorf-Hofmann A, Groitl H, Wittekind C, Ell C and Hahn EG:
Invasive carcinoma in colorectal adenomas: Multivariate analysis of
patient and adenoma characteristics. Endoscopy. 29:626–631. 1997.
View Article : Google Scholar : PubMed/NCBI
|
